Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety

被引：7
|
作者：
Trstenjak, Uros [1 ]
Ilas, Janez [1 ]
Kikelj, Danijel [1 ]
机构：
[1] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia
来源：
MEDCHEMCOMM | 2014年 / 5卷 / 02期
关键词：
PLATELET-AGGREGATION; THROMBIN; DISCOVERY; POTENT; WEIGHT; DESIGN; SERIES;
D O I：
10.1039/c3md00250k
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Replacement of the P-4 morpholin-3-one moiety in a selective factor Xa inhibitor rivaroxaban by 2-ethoxycarbonylpiperidine resulted in a dual factor Xa/thrombin inhibitor 24, possessing a K-i of 62 +/- 18 nM for factor Xa and a K-i of 353 +/- 75 nM for thrombin. Presented rationalization of dual activity provides a good starting point for "designing in" thrombin inhibitory activity to potent factor Xa inhibitor rivaroxaban.
引用
收藏
页码：197 / 202
页数：6
相关论文
共 50 条
  • [31] The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk
    Wiesen, Martin H. J.
    Blaich, Cornelia
    Mueller, Carsten
    Streichert, Thomas
    Pfister, Roman
    Michels, Guido
    CHEST, 2016, 150 (01) : E1 - E4
  • [32] Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells
    Ryoichi Sohma
    Masashi Sakuma
    Syotaro Obi
    Setsu Nishino
    Ken-ichi Inoue
    Satoko Kishimoto
    Tianyang Lu
    Shigeru Toyoda
    Teruo Inoue
    BMC Cardiovascular Disorders, 23
  • [33] A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban
    Hosny, Noha M.
    MICROCHEMICAL JOURNAL, 2020, 159
  • [34] The influence of the direct factor Xa inhibitor rivaroxaban on two different thrombin generation assays in patients with thrombophilia
    Siegemund, A.
    Siegemund, T.
    Scholz, U.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 706 - 706
  • [35] Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
    Kwong, Louis M.
    ORTHOPEDICS, 2012, 35 (06) : E932 - E938
  • [36] Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models
    Furugohri, T
    Shiozaki, Y
    Muramatsu, S
    Honda, Y
    Matsumoto, C
    Isobe, K
    Sugiyama, N
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 514 (01) : 35 - 42
  • [37] Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
    Perzborn, E.
    Heitmeier, S.
    Buetehorn, U.
    Laux, V.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (07) : 1054 - 1065
  • [38] ANTI-THROMBIN-III AND FACTOR-XA INHIBITOR IN ATHEROSCLEROSIS
    MARRA, R
    PAGANO, L
    DESTEFANO, V
    BIZZI, B
    HAEMOSTASIS, 1983, 13 (04) : 209 - 213
  • [39] Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin
    Hellstern, P.
    Stuerzebecher, U.
    Wuchold, B.
    Haubelt, H.
    Seyfert, U. T.
    Bauer, M.
    Vogt, A.
    Stuerzebecher, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (10) : 2119 - 2126
  • [40] INHIBITION OF FACTOR XA-INDUCED PLATELET-AGGREGATION BY A SELECTIVE THROMBIN INHIBITOR, ARGATROBAN
    KAWAI, H
    YAMAMOTO, T
    HARA, H
    TAMAO, Y
    THROMBOSIS RESEARCH, 1994, 74 (03) : 185 - 191
12345